妊娠期糖尿病孕妇胎盘LRP5与硬化蛋白表达增加
研究纳入26例妊娠期糖尿病(GDM)孕妇与34例非GDM孕妇及其新生儿,检测胎盘LRP5与硬化蛋白表达及脐血硬化蛋白浓度。GDM组胎盘硬化蛋白与LRP5组织评分均显著高于非GDM组,胎盘硬化蛋白与孕前BMI及母体空腹血糖呈正相关。
要点
- GDM组胎盘硬化蛋白组织评分65.08±17.09 vs 非GDM组11.45±2.33,P<.001。
- GDM组胎盘LRP5组织评分145.53±43.74 vs 非GDM组202.88±58.65,P<.001。
- 胎盘硬化蛋白与母体空腹血糖(r=0.475,P=.009)及孕前BMI(r=0.299,P=.043)正相关。
核心结论
- GDM孕妇胎盘硬化蛋白与LRP5表达高于非GDM孕妇,胎盘硬化蛋白与孕前BMI及母体空腹血糖正相关,可能反映母体高血糖下的适应机制。
研究设计与样本
- 研究纳入26例GDM孕妇与34例非GDM孕妇(均为白种人)及其新生儿,均来自大学医院妇产科。
- 胎盘LRP5采用免疫组化与Western blotting检测,胎盘硬化蛋白采用免疫组化检测,脐血清硬化蛋白采用ELISA检测。
- 从病历中获取人口学数据及孕24-28周母体空腹血糖浓度。
主要发现
- 胎盘硬化蛋白免疫组化强度值与LRP5免疫组化值(r=0.529,P<.001)及Western blotting值(r=0.398,P=.008)呈正相关。
- 胎盘硬化蛋白免疫组化强度值与孕前母体BMI(r=0.299,P=.043)及母体空腹血糖浓度(r=0.475,P=.009)呈正相关。
- GDM组胎盘硬化蛋白组织评分65.08±17.09 vs 非GDM组11.45±2.33,P<.001。
- GDM组胎盘LRP5组织评分145.53±43.74 vs 非GDM组202.88±58.65,P<.001。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The low-density lipoprotein receptor-related protein 5 (LRP5) and its inhibitor sclerostin, are key components of bone metabolism and potential contributors to type 2 diabetes mellitus susceptibility. This study aims at evaluating the expression of placental LRP5 and sclerostin in pregnancies with gestational diabetes mellitus (GDM) and investigate possible associations with umbilical sclerostin concentrations and clinical outcomes in mothers and their neonates. METHODS: Twenty-six GDM-mothers and 34 non-GDM mothers of Caucasian origin and their neonates admitted in a gynecology and obstetrics department of a university hospital were included in this study. Demographic data and maternal fasting glucose concentrations (24-28 weeks of gestation) were retrieved from the patients' medical records. Placental LRP5 was determined by immunohistochemistry (IHC) and Western blotting analysis; placental sclerostin was determined by IHC. Umbilical serum sclerostin concentrations were measured by ELISA. RESULTS: Placental sclerostin IHC intensity values were positively correlated with LRP5 values as detected either by IHC (r = 0.529; P < .001) or Western blotting (r = 0.398; P = .008), with pregestational maternal body mass index values (r = 0.299; P = .043) and with maternal fasting glucose concentrations (r = 0.475; P = .009). Placental sclerostin and LRP5 were significantly greater in GDM compared with non-GDM placentas (histo-score: 65.08 ± 17.09 vs 11.45 ± 2.33, P < .001; 145.53 ± 43.74 vs 202.88 ± 58.65, P < .001; respectively). DISCUSSION: Sclerostin and LRP5 were detected in human placentas. The overexpression of placental sclerostin and LRP5 values in GDM compared with non-GDM pregnancies, as well as the positive association of placental sclerostin values with pregestational maternal body mass index and maternal fasting glucose concentrations may indicate the development of an adaptive mechanism in face of maternal hyperglycemia.
引用
- Papadopoulou A, Thymara E, Maratou E, et al. Human Placental LRP5 and Sclerostin are Increased in Gestational Diabetes Mellitus Pregnancies. J Clin Endocrinol Metab. 2023. PMID: 36947076. doi:10.1210/clinem/dgad164
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。